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Abstract
The available research on switching from normal nicotine to very low nicotine content cigarettes 
shows minimal evidence of compensatory smoking. Mathematical estimations suggest that sub-
stantial compensation after switching to very low nicotine cigarettes would be impossible. It is 
likely that smokers who are unable to tolerate the extent of proposed nicotine reduction would 
switch to other sources of nicotine, rather than try to compensate by smoking more very low nico-
tine content cigarettes more intensely.
Introduction
As the Food and Drug Administration (FDA) considers implementing 
a reduced nicotine standard, it is important to consider how 
smokers’ behavior may change in response to very low nicotine 
content (VLNC) cigarettes. When faced with a potential reduction 
of nicotine availability, smokers may try to adjust their smoking 
behavior (either by smoking their cigarettes more intensely, or by 
increasing the number that they smoke per day) to maintain desired 
levels of nicotine intake. This is called compensation. In addicted cig-
arette smokers, there appears to be an optimal level of daily intake of 
nicotine that provides the desired rewards from smoking, including 
avoidance of nicotine withdrawal symptoms.1 Thus, smokers tend to 
take in a similar amount of nicotine from their cigarettes day after 
day. Compensation is seen when smokers switch from normal nico-
tine to low nicotine yield commercial cigarettes (ie, light cigarettes) 
and when the number of cigarettes one can smoke is limited.
How Does Compensation Occur?
Compensation for reduced nicotine yield cigarettes is relatively easy 
because the nicotine content of the tobacco filler (generally between 
10 and 15 mg) is similar for normal and low nicotine yield com-
mercial cigarettes. They are considered low yield based on smoking 
machine testing, which consists of taking a standard number of puffs 
of fixed duration and at fixed intervals until the cigarettes burn to 
the filter overwrap. Low-yield commercial cigarettes are engineered 
to burn more quickly and/or to have greater ventilation via changes 
in the cigarette paper and/or ventilation holes in the filter, com-
pared with normal nicotine yield cigarettes.2 The smoker can easily 
compensate by inhaling more deeply, taking more frequent puffs, 
blocking ventilation holes with fingers or mouth, and/or smoking 
more cigarettes per day (CPD). Compensation occurs with minimal 
effort and often without the smoker being aware of the change in 
behavior.
Compensation for smoking fewer cigarettes per day occurs 
through similar changes in puff topography. Assuming a cigarette 
contains 10–15 mg of nicotine, and the smoker takes in a systemic 
dose of 1 mg nicotine (both typical values), then the bioavailability 
is only about 6%–10%. A smoker can, by puffing more frequently 
and more intensively increase bioavailability 3–4 fold, such that a 
dose of 3–4 mg nicotine can be obtained per cigarette, effectively 
maintaining nicotine exposure even when the number of cigarettes 
smoked is reduced.3
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Is It Possible to Engage in Compensatory 
Smoking Behavior When Switching to VLNC 
Cigarettes?
Effectively compensating to maintain nicotine exposure is virtually 
impossible when switching to cigarettes with minimally addictive 
nicotine content (e.g., VLNC). The amount of nicotine needed to 
make cigarettes minimally addictive appears to be 0.4 to 0.5 mg nico-
tine per gram of tobacco in the tobacco rod (this may be different for 
other combusted products such as cigars).4 This represents a reduc-
tion of nicotine content of 95% or more compared with currently 
available commercial cigarettes. Assuming the tobacco in a cigarette 
weighs 0.7 gm, a cigarette containing 0.4 mg/gm tobacco would con-
tain 0.28 mg nicotine. Assuming the usual level of bioavailability, the 
systemic dose per cigarette would be around 0.025 mg. Assuming 
the most intensive compensatory inhalation of a 4-fold increase, the 
maximal systemic dose per cigarette would be about 0.1 mg. These 
doses are in contrast to the 1 mg or more taken systemically from 
a currently marketed cigarette. Assuming that a 10 CPD smoker is 
trying to maintain an intake of 10 mg nicotine per day, and assuming 
the most intensive compensation, it would require that the smoker 
smoke 100 CPD to achieve full compensation. It is likely impossible 
that a person could smoke 100 CPD at maximal intensity, so full 
compensation would be impossible. More likely, the smoker would 
try to smoke more intensively and smoke more cigarettes per day at 
first, find compensation impossible, and give up. As nicotine intake 
falls, one would predict that the level of nicotine dependence would 
likewise decline, and eventually the smoker would find the cigar-
ette unrewarding and quit. Alternatively, the smoker may seek other 
available forms of nicotine to satisfy their need for nicotine.
Is There Evidence of Compensation in VLNC 
Clinical Trials?
A number of clinical trials have assessed compensation across 
a variety of measures when smokers are switched from Normal 
Nicotine Content (NNC) to VLNC cigarettes and found minimal 
compensatory smoking behavior. Compensation has been assessed 
by measuring CPD, nicotine intake (blood levels of nicotine and 
cotinine or urine total nicotine equivalents), by exposure to tobacco 
combustion toxicant biomarkers (carbon monoxide, polycyclic aro-
matic hydrocarbons) and tobacco specific nitrosamines (NNAL), 
and by smoking topography. Trials have been done with single re-
duced nicotine content cigarettes, with switching from periods of 
4 weeks to 1  year, and with gradual and immediate reduction of 
nicotine content levels.4–8 In a study of smokers smoking a single 
cigarette of different nicotine content on separate days, the intake 
of nicotine based on area under the plasma nicotine concentration 
time curve was highly correlated with the nicotine content of the 
cigarette.9 Compensation when smoking the lowest nicotine con-
tent cigarette (0.6 mg nicotine per cigarette) compared with a 10 mg 
nicotine content cigarette was 33% with no difference in carbon 
monoxide exposure. Furthermore, a study by MacQueen et al. in-
dicated that increases in total puff volume were confined to the first 
few cigarettes and quickly returned to control levels.10
Several studies have looked at switching smokers to VLNC 
for weeks or up to 1  year.4–8,10 These studies were quite con-
sistent, showing a reduction of plasma cotinine or urine total nico-
tine equivalent levels of about 60% to 70% (data synthesized by 
Hatsukami et al. 2015).11 Overall, at the end of the study period, 
there was a significant decrease in CPD, although with gradual re-
duction there was a slight increase in CPD compared with baseline 
at medium nicotine content level, then a decline in CPD as nico-
tine content was further decreased. Expired carbon monoxide and 
polycyclic aromatic hydrocarbon exposure was unchanged by con-
dition, indicating no harmful over-smoking. Urine NNAL levels de-
creased in all reduced nicotine content cigarettes studies compared 
with baseline, but this does not inform compensation because the 
NNK levels in reduced nicotine content cigarettes are lower than 
currently marketed commercial cigarettes. One study found that 
total puff volume when smoking a single cigarette was significantly 
lower when smoking 0.4 mg/gm tobacco cigarettes compared with 
baseline.4 The observation that with gradual reduction there was evi-
dence consistent with some compensatory smoking with more CPD 
when cigarettes contained medium levels of nicotine supports the 
idea that nicotine levels need to be reduced to lower levels at which 
compensatory smoking is not feasible.
Are There Limitations in the Interpretation of 
Clinical Trials That Switch Smokers to VLNC 
Cigarettes?
The main limitation in interpreting the switching studies with 
respect to compensation is the noncompliance with research 
VLNCs. Based on biochemical assessments, noncompliance with 
study cigarettes is as high as 80%.12 Noncompliance is unavoid-
able in real world studies because usual brand cigarettes are 
readily available. Compliance is partial such that, as described 
above, nicotine intake decreases to 30%–40% of baseline, but 
this decline is less than expected based on the extent of nico-
tine reduction. Smokers typically smoked a few NNC cigarettes 
per day. Presumably, these cigarettes provide some of the nico-
tine that the addicted smoker cannot get from the VLNC. We do 
not yet know the extent of compensatory smoking behavior that 
would occur if higher nicotine content cigarettes were unavail-
able, as would be the case if all cigarettes were mandated to be 
VLNC. However, when confined to a residential research facility 
for 11 days, participants smoked fewer cigarettes per day and had 
lower exhaled carbon monoxide when randomized to very low 
nicotine versus control cigarettes.13
Another potential limitation is that experimental studies include 
subjects who have volunteered to participate. It is possible that more 
highly addicted smokers who might have trouble with nicotine re-
duction would not have volunteered to participate, or would have 
dropped out of studies.
Conclusions
The available research on switching from NNCs to VLNCs shows 
minimal evidence of compensatory smoking such that smokers do 
not smoke more cigarettes per day and are not exposed to higher 
levels of tobacco combustion toxicants. Furthermore, mathemat-
ical estimations based on the nicotine availability in VLNCs com-
pared with NNC cigarettes with consideration of potential increases 
in bioavailability that could occur with intensive smoking suggest 
that substantial compensation would be impossible. It is much more 
likely that smokers who are unable to tolerate the extent of pro-
posed nicotine reduction would switch to other sources of nicotine, 
rather than try to compensate by smoking more VLNC cigarettes 
more intensively.
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